As a health journey partner, we are dedicated to bringing new options to patients with an unmet need. In collaboration with Regeneron Pharmaceuticals, our current therapies for atopic dermatitis and rheumatoid arthritis are approved in the United States, Canada and Europe and we are seeking approvals in a number of other countries globally.
Current research conducted by Sanofi Genzyme, our global specialty care business unit, includes investigational treatments for asthma, nasal polyps, and eosinophilic esophagitis, each of which represent an area of significant need including those in emerging markets (1).
Moderate-to-Severe Atopic Dermatitis
Rheumatoid arthritis – commonly known as RA – is a chronic and debilitating autoimmune disease that primarily affects the joints, connective tissues, muscle, tendons, and fibrous tissue, causing pain, deformity and disability. There are more than 150 rheumatic conditions, with RA being one of the most common.
Although RA is typically thought of as a joint disease, the effects of RA can go beyond the joints. Living with RA can interfere with everyday life, and simple tasks can become difficult or take longer to complete. The symptoms of RA can also lead to stress or anxiety.
For more information about our work in Immunology, please consult the Sanofi Genzyme website.
(1) Emerging markets: world excluding U.S., Canada, Western Europe (France, Germany, UK, Italy, Spain, Greece, Cyprus, Malta, Belgium, Luxembourg, Portugal, the Netherlands, Austria, Switzerland, Sweden, Ireland, Finland, Norway, Iceland, Denmark), Japan, South Korea, Australia and New Zealand.